Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) reached a new 52-week high during trading on Thursday . The stock traded as high as $8.78 and last traded at $8.00, with a volume of 9492965 shares traded. The stock had previously closed at $7.42.
Analysts Set New Price Targets
TRVI has been the subject of several recent analyst reports. Wall Street Zen cut shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. Oppenheimer restated an "outperform" rating on shares of Trevi Therapeutics in a research note on Monday, June 2nd. HC Wainwright initiated coverage on shares of Trevi Therapeutics in a research note on Wednesday, May 28th. They issued a "buy" rating and a $21.00 target price for the company. Morgan Stanley initiated coverage on shares of Trevi Therapeutics in a research note on Thursday, August 21st. They issued an "overweight" rating and a $18.00 target price for the company. Finally, Cantor Fitzgerald initiated coverage on shares of Trevi Therapeutics in a research note on Tuesday, July 1st. They issued an "overweight" rating and a $25.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $20.11.
Check Out Our Latest Stock Analysis on Trevi Therapeutics
Trevi Therapeutics Stock Performance
The stock has a market capitalization of $879.86 million, a PE ratio of -17.20 and a beta of 0.71. The company's fifty day simple moving average is $6.95 and its two-hundred day simple moving average is $6.32.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. Sell-side analysts forecast that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.
Hedge Funds Weigh In On Trevi Therapeutics
Institutional investors have recently modified their holdings of the company. Alliancebernstein L.P. increased its position in Trevi Therapeutics by 19,064.5% during the second quarter. Alliancebernstein L.P. now owns 4,281,355 shares of the company's stock worth $23,419,000 after purchasing an additional 4,259,015 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Trevi Therapeutics during the fourth quarter worth approximately $17,099,000. Rubric Capital Management LP increased its position in Trevi Therapeutics by 88.0% during the second quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company's stock worth $46,669,000 after purchasing an additional 3,993,325 shares during the last quarter. Octagon Capital Advisors LP acquired a new position in Trevi Therapeutics during the first quarter worth approximately $20,895,000. Finally, Frazier Life Sciences Management L.P. increased its position in Trevi Therapeutics by 44.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock worth $43,939,000 after purchasing an additional 3,283,684 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company's stock.
Trevi Therapeutics Company Profile
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Read More
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.